Atyr Pharma Inc insider trading
Every open-market purchase and sale by Atyr Pharma Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Insider purchases, 5 years $962,720 3 trades by 1 insider Insider sales, 5 years $6,293 3 trades by 3 insiders
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Atyr Pharma Inc’s insiders pay?
From April 6, 2016 to May 28, 2026, 10 insiders reported 43 open-market purchases and 6 sales not made under a pre-set plan in Atyr Pharma Inc.
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Schimmel Paul | Director | 22 | — | — | 1 | — | May 28, 2026 |
| Shukla Sanjay | President and CEO | 10 | — | — | 0 | — | June 3, 2024 |
| Broadfoot Jill Marie | Chief Financial Officer | 3 | — | — | 0 | — | January 18, 2022 |
| Clarke John K | Director | 0 | — | — | 3 | — | May 25, 2021 |
| Ecor1 Capital Fund Qualified, L.P. | 10% owner | 1 | — | — | 2 | — | May 16, 2018 |
| Mendlein John | CEO and Director | 3 | — | — | 0 | — | December 26, 2018 |
| Amanullah Ashraf | Vice President, Manufacturing | 1 | — | — | 0 | — | December 21, 2016 |
| Coughlin Timothy | Director | 1 | — | — | 0 | — | June 3, 2024 |
| Gross Jane A | Director | 1 | — | — | 0 | — | March 17, 2025 |
| Matsuoka Grove | See Remarks | 1 | — | — | 0 | — | May 11, 2016 |